SOCMA has joined an international consortium, which works to enhance security and assure the quality and authenticity of products moving through the drug supply chain.
SOCMA is a non-voting observer member of the consortium, and intends to enhance its ongoing advocacy efforts on drug ingredient quality compliance.
The consortium follows four objectives: adopt standards and best practices to assist in improving the performance of the drug supply chain; develop new technologies that will secure the supply chain and detect tampering; monitor events within the supply chain in order to evaluate their impact; and serve as a platform for the sharing of GMP, GDP and EHS supplier audits in order to reduce the number of audits and increase the effectiveness of those performed.
The Rx-360 Consortium is designed to include the following in its voting membership: biotech firms, pharmaceutical and generic manufacturers, and their suppliers along with third party auditing firms who agree to the membership requirements.